Juan Carlos Prieto Villapún-rekin lankidetzan egindako argitalpenak (74)

2022

  1. Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH)

    Prostate, Vol. 82, Núm. 8, pp. 933-941

2020

  1. Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists

    Investigational New Drugs, Vol. 38, Núm. 3, pp. 746-754

2018

  1. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer

    Prostate, Vol. 78, Núm. 12, pp. 915-926

2017

  1. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells

    Molecular and Cellular Endocrinology, Vol. 446, pp. 59-69

2016

  1. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer

    Oncotarget, Vol. 7, Núm. 32, pp. 52195-52206

  2. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells

    Peptides, Vol. 86, pp. 153-161

  3. Transactivación de EGFR y HER2 inducida por la hormona liberadora de la hormona del crecimiento (GHRH) en cáncer de próstata avanzado

    Quintas Jornadas de Jóvenes Investigadores de la Universidad de Alcalá: Ciencias e Ingenierías

2015

  1. VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells

    Cellular Signalling, Vol. 27, Núm. 2, pp. 236-244

2014

  1. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models

    Investigational New Drugs, Vol. 32, Núm. 5, pp. 871-882

  2. Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression

    International Journal of Biochemistry and Cell Biology, Vol. 53, pp. 295-301

2013

  1. Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice

    Cancer Letters, Vol. 336, Núm. 1, pp. 196-203

  2. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer

    International Journal of Cancer, Vol. 132, Núm. 4, pp. 755-765

  3. Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma

    Molecular and Cellular Endocrinology, Vol. 365, Núm. 2, pp. 212-222

2012

  1. Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells

    Peptides, Vol. 38, Núm. 2, pp. 275-281

  2. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance

    Histology and Histopathology, Vol. 27, Núm. 8, pp. 1093-1101

  3. RNA interference-directed silencing of VPAC 1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells

    Molecular and Cellular Endocrinology, Vol. 348, Núm. 1, pp. 241-246

  4. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1823, Núm. 10, pp. 1676-1685

2010

  1. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer

    Peptides, Vol. 31, Núm. 11, pp. 2035-2045

  2. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095)

    International Journal of Cancer, Vol. 127, Núm. 8, pp. 1813-1822

  3. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1

    Cancer Letters, Vol. 299, Núm. 1, pp. 11-21